Wang Jingbo, Zhou Zongmei, Liang Jun, Feng Qinfu, Xiao Zefen, Hui Zhouguang, Wang Xiaozhen, Lv Jima, Chen Dongfu, Zhang Hongxing, Ji Zhe, Cao Jianzhong, Liu Lipin, Jiang Wei, Men Yu, Xu Cai, Dai Jiangrong, Yin Weibo, Wang Luhua
Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
Oncologist. 2016 Dec;21(12):1530-1537. doi: 10.1634/theoncologist.2016-0155. Epub 2016 Sep 14.
Consistent results are lacking as regards the comparative effectiveness of intensity-modulated radiotherapy (IMRT) versus three-dimensional conformal radiotherapy (3DCRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC).
Patients treated with definitive radiotherapy (RT) between 2002 and 2010 were retrospectively reviewed. Overall survival (OS), local-regional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS) were compared among patients irradiated with different techniques. The association between RT technique and survival indexes was assessed in a Cox proportional hazard regression model. Propensity score matching (PSM) was used to balance known confounding factors.
A total of 652 patients were eligible for analysis, including 206 with 3DCRT and 446 with IMRT. The median OS of the 3DCRT and IMRT groups were 19.4 and 23.3 months, with the 5-year rate of 13% and 19%, respectively (p = .043). Multivariate analysis identified IMRT as an independent favorable factor associated with LRPFS and DMFS. PSM analysis further verified the beneficial effect of IMRT on LRPFS. No difference in OS or PFS was observed between the two techniques. Subgroup analysis revealed that IMRT might be differentially more effective in both OS and LRPFS among patients who were female, nonsmokers, with adenocarcinoma, or without weight loss. There was a significant reduction of lung toxicity and similar esophagus toxicity in the IMRT group when compared with the 3DCRT group.
IMRT may confer superior LRPFS and comparable OS than can be achieved with 3DCRT in LA-NSCLC, along with the reduction of pulmonary toxicity.
Based on the largest number of patients from a single institution, the present study demonstrated that intensity-modulated radiotherapy (IMRT) could provide superior local-regional progression-free survival and similar overall survival compared with the traditional three-dimensional conformal radiotherapy (3DCRT) for stage III non-small cell lung cancer (NSCLC). IMRT was also found to be associated with the significantly decreased incidence of pulmonary toxicity. These results suggest that IMRT should be considered a surrogate for 3DCRT in locally advanced NSCLC and might be the preferred option for a female nonsmoker with adenocarcinoma and a potentially high risk of pulmonary toxicity from radiotherapy.
关于调强放疗(IMRT)与三维适形放疗(3DCRT)在局部晚期非小细胞肺癌(LA-NSCLC)患者中的比较疗效,目前尚无一致的结果。
对2002年至2010年间接受根治性放疗(RT)的患者进行回顾性分析。比较不同放疗技术患者的总生存期(OS)、局部区域无进展生存期(LRPFS)、远处转移无进展生存期(DMFS)和无进展生存期(PFS)。在Cox比例风险回归模型中评估放疗技术与生存指标之间的关联。采用倾向评分匹配(PSM)来平衡已知的混杂因素。
共有652例患者符合分析条件,其中206例接受3DCRT,446例接受IMRT。3DCRT组和IMRT组的中位OS分别为19.4个月和23.3个月,5年生存率分别为13%和19%(p = 0.043)。多因素分析确定IMRT是与LRPFS和DMFS相关的独立有利因素。PSM分析进一步证实了IMRT对LRPFS的有益作用。两种技术在OS或PFS方面未观察到差异。亚组分析显示,在女性、非吸烟者、腺癌患者或无体重减轻的患者中,IMRT在OS和LRPFS方面可能更具差异有效性。与3DCRT组相比,IMRT组的肺部毒性显著降低,食管毒性相似。
在LA-NSCLC中,IMRT可能比3DCRT具有更好的LRPFS和相当的OS,同时可降低肺部毒性。
基于来自单一机构的最大样本量患者,本研究表明,对于III期非小细胞肺癌(NSCLC),调强放疗(IMRT)与传统三维适形放疗(3DCRT)相比,可提供更好的局部区域无进展生存期和相似的总生存期。还发现IMRT与肺部毒性发生率显著降低相关。这些结果表明,在局部晚期NSCLC中,IMRT应被视为3DCRT的替代方案,对于腺癌且放疗可能有高肺部毒性风险的女性非吸烟者,IMRT可能是首选。